

Ru(II)-Catalyzed C6-Selective C–H Amidation of 2-Pyridones

Lei Zhang^a, Xiangyun Zheng^a, Jinkang Chen^a, Kang Cheng^a, Licheng Jin^a, Xinpeng Jiang^{a*}, and Chuanming Yu^{a,b*}

^aCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. of China.

^bCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, P. R. of China.

E-mail: ycm@zjut.edu.cn.


Contents

Contents	1
1. General information	2
2. General procedure for Ru(II)-catalyzed site-selective C–H amidation of pyridones	2
4. Gram-scale synthesis of 3a	3
5. Mechanistic studies	3
5.1 Deuteration experiment	3
5.2 KIE experiment.....	5
6. Competition experiments.....	7
7. Analytical data and copies of NMR spectra	9
7.1 Analytical data for products.....	9
7.2 Copies of NMR spectra	23
8. References	56

1. General information

All chemicals obtained from commercial sources were used as received unless otherwise noted. Substrate **1^[1]** and **2^[2]** were prepared by literature reports. The progress of the reactions was monitored by TLC with silica gel plates, and the visualization was carried out under UV light (254nm). Melting points were determined using a Büchi B-540 capillary melting point apparatus. NMR spectra were recorded on 400 MHz and 600 MHz spectrometers in the solvent indicated. Chemical shifts are reported downfield from TMS (=0) for ¹H NMR. For ¹³C NMR, chemical shifts are reported in the scale relative to CDCl₃ (= 77.0) and DMSO-d₆ (= 40.0). Infrared (IR) data were recorded as films on potassium bromide plates on a NICOLET iS50 FT-IR spectrometer. Mass spectra were measured with a low-resolution MS instrument using ESI ionization. HRMS spectra were recorded on an electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) mass spectrometer.

2. General procedure for Ru(II)-catalyzed site-selective C–H amidation of pyridones .




Synthesis of **3a** is representative. 2H-[1,2'-bipyridin]-2-one **1a** (0.4 mmol), **2a** (0.48 mmol), [RuCl₂(*p*-cymene)]₂ (0.004 mmol), AgSbF₆ (0.04 mmol) and PivOH (0.08 mmol) were dissolved in TFE (3 mL). The mixture was stirred at 50°C under argon atmosphere for 2 hours. The resulting mixture was cooled to room temperature and then diluted with dichloromethane. The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (petroleum ether/ethyl acetate =1/1→ethyl acetate) to give **3a** (114 mg, 98% yield) as an off-white solid.

4. Gram-scale synthesis of **3a**


2*H*-[1,2'-bipyridin]-2-one **1a** (1.730 g, 10 mmol), **2a** (1.958 g, 12 mmol), [RuCl₂(*p*-cymene)]₂ (32 mg, 0.5 mol %), AgSbF₆ (351 mg, 10 mol %) and PivOH (205mg, 20 mol %) were dissolved in TFE (30 mL) in a three-neck flask. The mixture was stirred at 50 °C under argon atmosphere for 24 hours. The resulting mixture was cooled to room temperature and then diluted with dichloromethane. The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (petroleum ether/ ethyl acetate =1/1→ethyl acetate) to give **3a** as an off-white solid (2.500 g, 86% yield).

5. Mechanistic studies^[3]


5.1 Deuteration experiment




2*H*-[1,2'-bipyridin]-2-one **1a** (0.4 mmol), [RuCl₂(*p*-cymene)]₂ (0.01 mmol), AgSbF₆ (0.04 mmol) and PivOH (0.08 mmol) were dissolved in TFE :D₂O or TFE:CD₃OD (1.5ml:1.5ml). The mixture was stirred at 50 °C under argon atmosphere for 2 hours. The resulting mixture was cooled to room temperature and then diluted with 50ml of dichloromethane, the combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (94% recovered). D-incorporation was determined by ¹H NMR (~0% D-incorporation was observed).



5.2 KIE experiment





Compound **1a** (0.1 mmol) and $[\text{D}_1]\text{-1a}$ (0.1 mmol), **2a** (0.48 mmol), $[\text{RuCl}_2(p\text{-cymene})]_2$ (0.01 mmol), AgSbF_6 (0.04 mmol) and PivOH (0.08 mmol) were dissolved in TFE (3 mL). The mixture was stirred at 50 °C under argon atmosphere for 15 min. The resulting mixture was cooled to room temperature and then diluted with dichloromethane, the combined organic layer was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by flash chromatography. The remaining starting materials were recovered in 30% and analyzed by ^1H NMR to determine the ratio of **1m** and $[\text{D}_1]\text{-1m}$. ($K_{(H)}/K_{(D)} = (1-0.48)/0.48 = 1.08$)




1a

[D1]-**1a**




1a




6. Competition experiments


6.1 2-Pyridones




To an oven-dried 10 mL pressure tube was added **1c** (42 mg, 0.20 mmol), **1a** (38 mg, 0.20 mmol), **2a** (33mg, 0.2 mmol), $[\text{RuCl}_2(p\text{-cymene})]_2$ (0.01 mmol), AgSbF_6 (0.04 mmol), PivOH (0.08 mmol), and TFE (3 mL) under Ar atmosphere. The mixture was stirred for 2 h at 50 °C before diluted with DCM, washed with brine, and then concentrated in vacuum. The ratio of product **4c**/**4a** was analyzed by HPLC (Welch Ultimate Plus 4.6 x 250mm, 20% ACN/H₂O, 0.8 mL/min, 210 nm. $t_{4c} = 18.46$ min, $t_{4a} = 16.05$ min).



6.2 Oxazolones



To an oven-dried 10 mL pressure tube was added substrate **2j** (40 mg, 0.20 mmol), substrate **2g** (36 mg, 0.20 mmol), **1a** (35mg, 0.2 mmol), $[\text{RuCl}_2(p\text{-cymene})]_2$ (0.01 mmol), AgSbF_6 (0.04 mmol) and PivOH (0.08 mmol) were dissolved in TFE (3 mL) under Ar atmosphere. The mixture was stirred for 2 h at 50 °C. The mixture was then cooled to room temperature, diluted with DCM, washed with brine, concentrated in vacuum. The ratio of product **3j/3g** was analyzed by HPLC (Welch Ultimate Plus 4.6 x 250mm, 20% ACN/H₂O, 0.8 mL/min, 210 nm. $t_{3j} = 12.73 \text{ min}$, $t_{3g} = 11.68 \text{ min}$).



面积百分比报告

排序	:	信号
乘积因子	:	1.0000
稀释因子	:	1.0000
内标中不使用乘积因子和稀释因子		


信号 1: DAD1 A, Sig=210.4 Ref=off

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]	峰面积 %
1	11.686	BB	0.0973	1317.18884	209.77737	36.2059
2	12.732	BB	0.0965	2320.85693	373.67096	63.7941

7. Analytical data and copies of NMR spectra

7.1 Analytical data for products.


N-(2-oxo-2H-[1,2'-bipyridin]-6-yl)benzamide (3a):



3a

Product **3a** was isolated as an off-white solid (114 mg, 98%); m.p. 151-154 °C (146-148°C)^[3]; ¹H NMR (600 MHz, CDCl₃) δ 9.47 (s, 1H), 8.68 (d, *J* = 3.8 Hz, 1H), 7.96 (td, *J* = 8.0, 1.6 Hz, 1H), 7.64 (d, *J* = 8.0 Hz, 1H), 7.59 – 7.55 (m, 2H), 7.54 – 7.44 (m, 3H), 7.45-7.40 (m, 2H), 7.09 (d, *J* = 7.4 Hz, 1H), 6.50 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 164.22, 162.52, 150.28, 148.52, 141.08, 139.48, 139.42, 133.27, 132.54, 128.85, 126.87, 125.45, 124.39, 116.74, 99.07. IR (KBr) *v* : 3442, 3137, 3061, 1676, 1600, 1529, 1367, 1275. HRMS (ESI) *m/z* calcd for C₁₇H₁₄N₃O₂ [M + H]⁺ 292.1081, found 292.1085.

N-(2-oxo-2H-[1,2'-bipyridin]-6-yl)-4-(trifluoromethyl)benzamide (3b):




3b

Product **3b** was isolated as an off-white solid (141 mg, 98%); m.p. 179-182 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.72 (s, 1H), 8.64 (d, *J* = 3.8 Hz, 1H), 7.96 (td, *J* = 8.0, 1.8 Hz, 1H), 7.72 – 7.67 (m, 4H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.52-7.42 (m, 2H), 7.06 (d, *J* = 7.2 Hz, 1H), 6.53 (d, *J* = 8.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 163.02, 162.43, 150.31, 148.39, 140.88, 139.44, 138.91, 136.57, 134.10 (d, *J* = 32.8 Hz), 127.40, 125.91 (q, *J* = 3.8 Hz), 125.43, 124.43, 123.35 (d, *J* = 272.8 Hz), 117.42,

99.39. ^{19}F NMR (376 MHz, CDCl_3) δ -63.11. IR (KBr) ν : 3439, 3059, 1678, 1601, 1532, 1330, 1268. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{13}\text{F}_3\text{N}_3\text{O}_2$ [$\text{M} + \text{H}]^+$ 360.0954, found 360.0944.


4-fluoro-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3c):



3c

Product **3c** was isolated as an off-white solid (120 mg, 97%); m.p. 213-215 °C; ^1H NMR (600 MHz, CDCl_3) δ 9.51 (s, 1H), 8.64 (d, $J = 3.6$ Hz, 1H), 7.95 (t, $J = 7.4$ Hz, 1H), 7.64 (d, $J = 8.0$ Hz, 1H), 7.62-7.56 (m, 2H), 7.51 – 7.40 (m, 2H), 7.12-7.05 (m, 2H), 7.03 (d, $J = 7.4$ Hz, 1H), 6.50 (d, $J = 9.2$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 165.20 (d, $J = 254.4$ Hz), 163.19, 150.35, 148.41, 140.95, 139.41, 139.27, 129.50 (d, $J = 3.1$ Hz), 129.35 (d, $J = 9.2$ Hz), 125.41, 124.36, 116.96, 116.07, 115.92, 99.18. ^{19}F NMR (376 MHz, CDCl_3) δ -105.78. IR (KBr) ν : 3431, 3056, 1676, 1603, 1537, 1471, 1437, 1365, 1280. HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{13}\text{FN}_3\text{O}_2$ [$\text{M} + \text{H}]^+$ 310.0986, found 310.099.

4-chloro-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3d):




3d

Product **3d** was isolated as an off-white solid (128 mg, 98%); m.p. 202-206 °C; ^1H NMR (600 MHz, CDCl_3) δ 9.57 (s, 1H), 8.63 (d, $J = 4.2$ Hz, 1H), 7.95 (t, $J = 7.4$ Hz, 1H), 7.63 (d, $J = 8.0$ Hz, 1H), 7.51 (d, $J = 8.4$ Hz, 2H), 7.49 – 7.42 (m, 2H), 7.40-7.36 (m, 2H), 7.02 (d, $J = 7.4$ Hz, 1H), 6.51 (d, $J = 9.2$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 163.20, 162.44, 150.36, 148.44, 140.95, 139.42, 139.13, 138.95, 131.70, 129.16, 128.27, 125.44, 124.38, 117.03, 99.05. IR (KBr) ν : 3439, 3184, 2989, 1682,

1537, 1471, 1432, 1366, 1274. HRMS (ESI) m/z calcd for $C_{17}H_{13}ClN_3O_2$ [M + H]⁺ 326.0691, found 326.0693.


4-bromo-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3e):



3e

Product **3e** was isolated as an off-white solid (139 mg, 94%); m.p. 201-206 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.56 (s, 1H), 8.63 (dd, *J* = 4.8, 1.2 Hz, 1H), 7.95 (td, *J* = 8.0, 1.9 Hz, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.57 – 7.53 (m, 2H), 7.47 (dd, *J* = 9.2, 7.5 Hz, 1H), 7.45 – 7.42 (m, 3H), 7.03 (dd, *J* = 7.6, 0.8 Hz, 1H), 6.50 (dd, *J* = 9.2, 1.0 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 163.35, 162.45, 150.33, 148.41, 140.94, 139.42, 139.12, 132.15, 132.13, 128.41, 127.46, 125.42, 124.38, 117.07, 99.17. IR (KBr) ν : 3427, 3180, 3092, 2992, 1682, 1533, 1432, 1366, 1277. HRMS (ESI) m/z calcd for $C_{17}H_{13}BrN_3O_2$ [M + H]⁺ 370.0186, found 370.0175.


4-methyl-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3f):



3f

Product **3f** was isolated as an off-white solid (58 mg, 48%); m.p. 201-203 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.36 (s, 1H), 8.68 (d, *J* = 4.4 Hz, 1H), 7.94 (td, *J* = 7.8, 1.8 Hz, 1H), 7.61 (d, *J* = 8.2 Hz, 1H), 7.50 – 7.40 (m, 4H), 7.20 (d, *J* = 8.2 Hz, 2H), 7.09 (d, *J* = 7.6 Hz, 1H), 6.48 (d, *J* = 9.2 Hz, 1H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.14, 162.55, 150.30, 148.54, 143.29, 141.10, 139.50, 139.47, 130.40, 129.51, 126.87, 125.47, 124.38, 116.54, 98.89, 21.45. IR (KBr) ν : 3423, 3246, 3039, 1676, 1603, 1537, 1435, 1366, 1280. HRMS (ESI) m/z calcd for $C_{18}H_{16}N_3O_2$ [M + H]⁺ 306.1237, found 306.1251.

3-methyl-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3g):




3g

Product **3g** was isolated as an off-white solid (79 mg, 80%); m.p. 147-151 °C;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.19 (s, 1H), 8.56 (d, *J* = 4.8 Hz, 1H), 7.91 (td, *J* = 7.8, 1.8 Hz, 1H), 7.60 (dd, *J* = 9.2, 7.2 Hz, 1H), 7.44 – 7.36 (m, 2H), 7.30 (d, *J* = 3.6 Hz, 1H), 7.28 – 7.22 (m, 3H), 6.49 (d, *J* = 9.2 Hz, 1H), 6.37 (d, *J* = 7.0 Hz, 1H), 2.27 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 166.27, 162.79, 150.75, 149.21, 141.26, 141.06, 138.51, 138.12, 133.34, 133.03, 128.67, 128.37, 125.04, 124.88, 124.46, 119.08, 104.46, 21.26. IR (KBr) ν : 3169, 3058, 2987, 1671, 1586, 1518, 1468, 1377, 1280. HRMS (ESI) *m/z* calcd for C₁₈H₁₆N₃O₂ [M + H]⁺ 306.1237, found 306.1243.

3-methoxy-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3h):




3h

Product **3h** was isolated as an off-white solid (123 mg, 96%); m.p. 148-151 °C;

¹H NMR (400 MHz, CDCl₃) δ 9.43 (s, 1H), 8.68 (s, 1H), 7.96 (t, *J* = 7.6 Hz, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.50-7.40 (m, 2H), 7.30 (t, *J* = 8.4 Hz, 1H), 7.17 (s, 1H), 7.09 (d, *J* = 7.4 Hz, 1H), 7.07 – 6.99 (m, 2H), 6.50 (d, *J* = 9.2 Hz, 1H), 3.81 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.08, 162.52, 159.90, 150.29, 148.63, 141.04, 139.39, 139.33, 134.67, 129.81, 125.34, 124.35, 118.73, 118.42, 116.73, 112.25, 98.95, 55.39. IR (KBr) ν : 3445, 3062, 2837, 1670, 1597, 1525, 1414, 1366, 1272. HRMS (ESI) *m/z* calcd for C₁₈H₁₅N₃NaO₃ [M + Na]⁺ 344.1006, found 344.1004.


3-fluoro-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3i):



3i

Product **3i** was isolated as an off-white solid (117 mg, 95%); m.p. 178-182 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.12 (d, *J* = 15.6 Hz, 1H), 8.72 (dd, *J* = 5.0, 1.2 Hz, 1H), 8.06 (td, *J* = 8.0, 1.8 Hz, 1H), 7.96 (td, *J* = 7.8, 1.8 Hz, 1H), 7.55 (d, *J* = 8.0 Hz, 1H), 7.52 – 7.44 (m, 3H), 7.26 (td, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.02 (ddd, *J* = 12.4, 8.2, 0.8 Hz, 1H), 6.50 (dd, *J* = 9.2, 0.8 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 163.51, 162.94 (d, *J* = 2.5 Hz), 162.43, 161.86, 150.31, 148.46, 140.90, 139.38, 139.06, 135.52 (d, *J* = 6.9 Hz), 130.54 (d, *J* = 7.9 Hz), 124.87 (d, *J* = 150.7 Hz), 122.23 (d, *J* = 3.0 Hz), 119.56 (d, *J* = 21.3 Hz), 117.14, 114.39 (d, *J* = 23.3 Hz), 99.18. ¹⁹F NMR (376 MHz, CDCl₃) δ -113.96. IR (KBr) ν : 3415, 3054, 1682, 1529, 1473, 1380, 1296, 1271. HRMS (ESI) *m/z* calcd for C₁₇H₁₃FN₃O₂ [M + H]⁺ 310.0986, found 310.0982.


3-chloro-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3j):



3j


Product **3j** was isolated as an off-white solid (91 mg, 70%); m.p. 188-191 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.66 (s, 1H), 8.66 (d, *J* = 3.8 Hz, 1H), 7.96 (td, *J* = 8.0, 1.4 Hz, 1H), 7.64 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 1.6 Hz, 1H), 7.51 – 7.42 (m, 4H), 7.35 (t, *J* = 8.0 Hz, 1H), 7.04 (d, *J* = 7.4 Hz, 1H), 6.51 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 162.85, 162.41, 150.31, 148.38, 140.92, 139.49, 139.04, 135.06, 135.05, 132.49, 130.16, 127.31, 125.45, 124.94, 124.41, 117.18, 99.12. IR (KBr) ν : 3451, 2965, 1680, 1605, 1537, 1441, 1373, 1252. HRMS (ESI) *m/z* calcd for C₁₇H₁₃ClN₃O₂ [M + H]⁺ 326.0691, found 326.0684.

3-bromo-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3k):




Product **3k** was isolated as an off-white solid (145 mg, 98%); m.p. 198 - 199 °C;
¹H NMR (600 MHz, CDCl₃) δ 9.67 (s, 1H), 8.69 (d, *J* = 3.4 Hz, 1H), 7.97 (t, *J* = 7.6 Hz, 1H), 7.70-7.62 (m, 3H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.51-7.44 (m, 2H), 7.30 (t, *J* = 8.0 Hz, 1H), 7.05 (d, *J* = 7.4 Hz, 1H), 6.51 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 162.71, 162.41, 150.34, 148.45, 140.92, 139.45, 139.02, 135.39, 135.23, 130.41, 130.15, 125.48, 125.40, 124.41, 122.97, 117.15, 99.04. IR (KBr) ν : 3428, 3100, 2946, 1678, 1603, 1533, 1470, 1373, 1251. HRMS (ESI) *m/z* calcd for C₁₇H₁₃BrN₃O₂ [M + H]⁺ 370.0186, found 370.0195.

2-chloro-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3m)




Product **3m** was isolated as an off-white solid (65 mg, 50%); m.p. 170-175 °C;
¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H), 8.53 (dd, *J* = 4.8, 1.2 Hz, 1H), 7.95 (td, *J* = 7.8, 1.8 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.57 – 7.52 (m, 1H), 7.48 (dd, *J* = 8.8, 7.8 Hz, 1H), 7.45 – 7.34 (m, 2H), 7.32-7.26 (m, 2H), 7.12-7.05 (m, 1H), 6.51 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 163.58, 162.48, 149.95, 149.32, 140.89, 139.30, 138.72, 133.51, 132.31, 130.71, 130.39, 130.18, 127.30, 125.22, 124.43, 117.30, 99.56. IR (KBr) ν : 3443, 2965, 1677, 1604, 1519, 1429, 1370, 1252. HRMS (ESI) *m/z* calcd for C₁₇H₁₃ClN₃O₂ [M + H]⁺ 326.0691, found 326.0685.

2-fluoro-N-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (3n):




Product **3n** was isolated as an off-white solid (108 mg, 87%); m.p. 183 -186 °C;
¹H NMR (600 MHz, CDCl₃) δ 9.61 (s, 1H), 8.66 (dd, *J* = 4.8, 1.2 Hz, 1H), 7.95 (td, *J* = 8.0, 1.8 Hz, 1H), 7.64 (d, *J* = 8.2 Hz, 1H), 7.50 – 7.43 (m, 2H), 7.42 – 7.36 (m, 1H), 7.33 – 7.28 (m, 2H), 7.25 – 7.19 (m, 1H), 7.05 (dd, *J* = 7.4, 0.8 Hz, 1H), 6.51 (dd, *J* = 9.2, 1.0 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 162.46, 160.89, 160.25 (d, *J* = 3.2 Hz), 159.24, 149.72 (d, *J* = 8.4 Hz), 140.92, 139.21 (d, *J* = 3.0 Hz), 134.50 (d, *J* = 9.6 Hz), 132.34 (d, *J* = 0.8 Hz), 125.08 (d, *J* = 3.2 Hz), 124.84, 124.39, 119.80 (d, *J* = 10.6 Hz), 116.71, 116.13, 115.97, 99.09. ¹⁹F NMR (376 MHz, CDCl₃) δ -110.79. IR (KBr) ν : 3424, 3181, 3062, 2995, 1678, 1603, 1529, 1417, 1370, 1277. HRMS (ESI) *m/z* calcd for C₁₇H₁₃FN₃O₂ [M + H]⁺ 310.0986, found 310.0981.

***N*-(2-oxo-2*H*-[1,2'-bipyridin]-6-yl)thiophene-2-carboxamide (3o):**



Product **3o** was isolated as an off-white solid (59 mg, 50%); m.p. 166 -170 °C;
¹H NMR (600 MHz, CDCl₃) δ 9.46 (s, 1H), 8.72 (d, *J* = 3.2 Hz, 1H), 7.97 (t, *J* = 7.4 Hz, 1H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 4.8 Hz, 1H), 7.46 (t, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 3.4 Hz, 1H), 7.08-7.00 (m, 2H), 6.49 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 162.40, 158.50, 150.32, 148.55, 141.00, 139.40, 139.00, 137.89, 131.82, 129.01, 127.99, 125.37, 124.35, 116.64, 98.73. IR (KBr) ν : 3440, 3092, 2971, 1651, 1526, 1288 HRMS (ESI) *m/z* calcd for C₁₅H₁₂N₃O₂S [M + H]⁺ 298.0645, found 298.0656.


N-(2-oxo-2H-[1,2'-bipyridin]-6-yl)pivalamide (3p):



Product **3p** was isolated as an off-white solid (57 mg, 53%); m.p. 176-180 °C;

¹H NMR (600 MHz, CDCl₃) δ 8.67 (s, 1H), 8.48 (s, 1H), 7.96 (t, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 7.8 Hz, 1H), 7.48-7.40 (m, 2H), 6.88 (d, *J* = 6.2 Hz, 1H), 6.45 (d, *J* = 9.2 Hz, 1H), 1.00 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 175.77, 162.49, 150.26, 148.85, 140.93, 139.30, 139.27, 125.13, 124.24, 116.42, 98.98, 39.74, 26.88. IR (KBr) *v* : 3161, 3083, 2964, 2870, 1683, 1605, 1540, 1385, 1270. HRMS (ESI) *m/z* calcd for C₁₅H₁₇N₃NaO₂ [M + Na]⁺ 294.1213, found 294.1218.


N-(3-methyl-2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (4a):



4a

Product **4a** was isolated as an off-white solid (100 mg, 82%); m.p. 202 -204 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.22 (s, 1H), 8.63 (d, *J* = 3.8 Hz, 1H), 7.91 (td, *J* = 8.0, 1.8 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 7.4 Hz, 2H), 7.50 (t, *J* = 7.4 Hz, 1H), 7.44-7.36 (m, 3H), 7.34 (d, *J* = 7.6 Hz, 1H), 6.91 (d, *J* = 7.6 Hz, 1H), 2.17 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 164.34, 162.74, 150.70, 148.53, 139.11, 137.89, 136.63, 133.35, 132.35, 128.76, 126.81, 126.24, 125.35, 124.14, 99.59, 16.82. IR (KBr) ν : 3451, 2923, 2778, 1667, 1615, 1559, 1434, 1280. HRMS (ESI) *m/z* calcd for C₁₈H₁₆N₃O₂ [M + H]⁺ 306.1237, found 306.1247.


N-(3-fluoro-2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (4b):



4b

Product **4b** was isolated as an off-white solid (115 mg, 93%); m.p. 242-245 °C; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.34 (s, 1H), 8.57 (d, *J* = 3.8 Hz, 1H), 7.94 (td, *J* = 7.8, 1.8 Hz, 1H), 7.62 (dd, *J* = 10.2, 8.0 Hz, 1H), 7.53 – 7.40 (m, 5H), 7.39-7.34 (m, 2H), 6.36 (dd, *J* = 8.0, 4.2 Hz, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 166.55, 156.21 (d, *J* = 28.0 Hz), 152.34, 149.97, 149.90, 149.48, 138.89, 136.60 (d, *J* = 4.8 Hz), 133.16, 132.58, 128.85, 127.84, 124.88 (d, *J* = 25.4 Hz), 121.89 (d, *J* = 17.4 Hz), 103.37 (d, *J* = 5.8 Hz). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -133.83. IR (KBr) ν : 3439, 3211, 2947, 1666, 1618, 1560, 1515, 1473, 1434, 1379, 1277. HRMS (ESI) *m/z* calcd for C₁₇H₁₃FN₃O₂ [M + H]⁺ 310.0986, found 310.0988.


N-(3-chloro-2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (4c):



4c

Product **4c** was isolated as an off-white solid (106 mg, 82%); m.p. 228-233 °C; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.39 (s, 1H), 8.57 (dd, *J* = 5.6, 1.8 Hz, 1H), 8.02 – 7.88 (m, 2H), 7.53 – 7.48 (m, 1H), 7.48 – 7.42 (m, 4H), 7.40-7.35 (m, 2H), 6.46 (d, *J* = 7.8 Hz, 1H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 166.33, 158.83, 150.40, 149.39, 140.26, 139.42, 138.84, 133.14, 132.61, 128.83, 127.85, 124.94, 124.79, 123.42, 104.60. IR (KBr) ν : 3213, 3106, 2968, 1670, 1591, 1522, 1357, 1270. HRMS (ESI) *m/z* calcd for C₁₇H₁₃ClN₃O₂ [M + H]⁺ 326.0691, found 326.0690.


N-(3-bromo-2-oxo-2*H*-[1,2'-bipyridin]-6-yl)benzamide (4d):



4d


Product **4d** was isolated as an off-white solid (136 mg, 92%); m.p. 210 -212 °C; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.35 (s, 1H), 8.62 – 8.52 (m, 1H), 8.13 (d, *J* = 7.8 Hz, 1H), 7.94 (td, *J* = 7.8, 1.8 Hz, 1H), 7.52 – 7.48 (m, 1H), 7.48 – 7.42 (m, 4H), 7.40-7.35 (m, 2H), 6.40 (d, *J* = 7.8 Hz, 1H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 166.25, 158.94, 150.52, 149.37, 143.17, 141.03, 138.83, 133.12, 132.63, 128.85, 127.85, 124.93, 124.79, 113.77, 105.22. IR (KBr) ν : 3443, 3057, 1670, 1628, 1592, 1529, 1472, 1434, 1358, 1262. HRMS (ESI) *m/z* calcd for C₁₇H₁₃BrN₃O₂ [M + H]⁺ 370.0186, found 370.0174.

N-(2-oxo-3-(trifluoromethyl)-2H-[1,2'-bipyridin]-6-yl)benzamide (4e):



Product **4e** was isolated as an off-white solid (40 mg, 28%); m.p. 211-219 °C;
¹H NMR (400 MHz, CDCl₃) δ 9.75 (s, 1H), 8.72 (d, *J* = 3.6 Hz, 1H), 8.00 (t, *J* = 7.8 Hz, 1H), 7.88 (d, *J* = 8.2 Hz, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.62 – 7.48 (m, 4H), 7.46–7.40 (m, 2H), 7.33 (d, *J* = 8.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 164.09, 158.32, 149.27, 148.79, 143.54, 140.69 (q, *J* = 4.8 Hz), 139.64, 133.04, 132.86, 129.04, 126.93, 125.55, 124.96, 122.76 (d, *J* = 271.0 Hz), 115.50 (q, *J* = 31.6 Hz), 95.79. ¹⁹F NMR (376 MHz, CDCl₃) δ -65.03. IR (KBr) ν : 3408, 3152, 3058, 1682, 1560, 1525, 1375, 1252. HRMS (ESI) *m/z* calcd for C₁₈H₁₂F₃N₃NaO₂ [M + Na]⁺ 382.0774, found 382.0772.


N-(4-methyl-2-oxo-2H-[1,2'-bipyridin]-6-yl)benzamide (4f):



Product **4f** was isolated as an off-white solid (114 mg, 93%); m.p. 197-200 °C;
¹H NMR (600 MHz, CDCl₃) δ 9.56 (s, 1H), 8.65 (d, *J* = 4.0 Hz, 1H), 7.96–7.88 (m, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.60 – 7.55 (m, 2H), 7.52 (t, *J* = 7.4 Hz, 1H), 7.41 (t, *J* = 7.8 Hz, 3H), 6.98 (d, *J* = 1.0 Hz, 1H), 6.31 (s, 1H), 2.27 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 164.24, 162.34, 152.93, 150.42, 148.38, 139.21, 138.21, 133.35, 132.46, 128.81, 126.83, 125.48, 124.13, 115.33, 101.45, 21.97. IR (KBr) ν : 3247, 3057, 2916, 1685, 1525, 1435, 1351, 1273. HRMS (ESI) *m/z* calcd for C₁₈H₁₆N₃O₂

$[M + H]^+$ 306.1237, found 306.1245.


N-(4-(benzyloxy)-2-oxo-2H-[1,2'-bipyridin]-6-yl)benzamide (4g):



4g

Product **4g** was isolated as an off-white solid (122 mg, 77%); m.p. 172-175 °C; ^1H NMR (600 MHz, CDCl_3) δ 9.66 (s, 1H), 8.66 (s, 1H), 7.93 (t, $J = 7.8$ Hz, 1H), 7.65-7.54 (m, 3H), 7.52 (t, $J = 7.4$ Hz, 1H), 7.46 – 7.38 (m, 7H), 7.38 – 7.34 (m, 1H), 7.03 (d, $J = 2.0$ Hz, 1H), 5.93 (s, 1H), 5.09 (s, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.22, 164.18, 163.61, 150.35, 148.30, 139.50, 139.21, 135.21, 133.34, 132.52, 128.84, 128.66, 128.37, 127.55, 126.87, 125.66, 124.08, 94.66, 93.67, 70.32. IR (KBr) ν : 3442, 3061, 1666, 1556, 1532, 1436, 1352, 1263. HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}_3$ $[M + H]^+$ 398.1499, found 398.1492.

N-(2-oxo-4-(trifluoromethyl)-2H-[1,2'-bipyridin]-6-yl)benzamide (4h):




4h

Product **4h** was isolated as an off-white solid (82 mg, 57%); m.p. 173-179 °C; ^1H NMR (600 MHz, CDCl_3) δ 9.69 (s, 1H), 8.78 – 8.65 (m, 1H), 8.01 (td, $J = 8.0, 1.8$ Hz, 1H), 7.64 (d, $J = 8.2$ Hz, 1H), 7.60 – 7.53 (m, 3H), 7.51 (dd, $J = 7.0, 5.4$ Hz, 1H), 7.44 (t, $J = 7.8$ Hz, 2H), 7.40 (d, $J = 1.6$ Hz, 1H), 6.75 (s, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 164.08, 161.49, 149.65, 148.84, 142.63 (d, $J = 33.8$ Hz), 141.31, 139.75,


132.92, 132.90, 129.01, 126.88, 125.21, 124.87, 122.12 (d, $J = 274.2$ Hz), 113.56 (q, $J = 4.2$ Hz), 93.34 (d, $J = 2.8$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -67.01. IR (KBr) ν : 3146, 3078, 2927, 1702, 1614, 1525, 1438, 1358, 1284. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{13}\text{F}_3\text{N}_3\text{O}_2$ [$\text{M} + \text{H}]^+$ 360.0954, found 360.0951.

N-(1-oxo-2-(pyridin-2-yl)-1,2-dihydroisoquinolin-3-yl)benzamide (4k):



Product **4k** was isolated as an off-white solid (134 mg, 98%); m.p. 199-202 °C (m.p. 96-98 °C)^[3]; ^1H NMR (600 MHz, CDCl_3) δ 9.36 (s, 1H), 8.55 (d, $J = 4.2$ Hz, 1H), 8.37 (d, $J = 8.0$ Hz, 1H), 7.91 (td, $J = 7.8, 1.8$ Hz, 1H), 7.67 – 7.61 (m, 2H), 7.59 – 7.55 (m, 2H), 7.52 – 7.47 (m, 2H), 7.46 – 7.42 (m, 1H), 7.40-7.34 (m, 3H), 7.19 (s, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 165.04, 162.74, 150.80, 148.41, 139.09, 136.89, 133.56, 133.21, 133.07, 132.21, 128.69, 128.04, 126.92, 126.42, 126.37, 125.49, 124.26, 123.92, 100.79. IR (KBr) ν : 3165, 3059, 2965, 1666, 1517, 1372, 1269. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{16}\text{N}_3\text{O}_2$ [$\text{M} + \text{H}]^+$ 342.1237, found 342.1238.


N-(7-bromo-1-oxo-2-(pyridin-2-yl)-1,2-dihydroisoquinolin-3-yl)benzamide (4l):



Product **4l** was isolated as an off-white solid (168 mg, 98%); m.p. 200 -205 °C; ^1H NMR (600 MHz, CDCl_3) δ 9.47 (s, 1H), 8.54 (d, $J = 3.9$ Hz, 1H), 8.19 (d, $J = 8.6$ Hz, 1H), 7.92 (td, $J = 7.8, 1.8$ Hz, 1H), 7.62 (t, $J = 5.2$ Hz, 2H), 7.59 – 7.54 (m, 2H), 7.54 – 7.49 (m, 2H), 7.43 – 7.37 (m, 3H), 7.12 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ

164.89, 162.25, 150.48, 148.51, 139.28, 138.41, 134.47, 133.41, 132.40, 129.80, 129.62, 128.78, 128.64, 128.53, 126.92, 125.52, 124.16, 122.75, 98.99. IR (KBr) ν : 3443, 3057, 1670, 1628, 1592, 1529, 1472, 1434, 1358, 1262. HRMS (ESI) m/z calcd for $C_{21}H_{14}BrN_3NaO_2 [M + Na]^+$ 442.0162, found 442.0167.


N-(6-oxo-1-(thiazol-2-yl)-1,6-dihdropyridin-2-yl)benzamide (4m):





4m


Product **4m** was isolated as an yellow solid (58 mg, 49%); m.p. 136-139 °C; 1H NMR (400 MHz, DMSO) δ 11.84 (s, 1H), 7.84 (dd, $J = 10.8, 3.6$ Hz, 2H), 7.73 (d, $J = 7.6$ Hz, 2H), 7.69 – 7.56 (m, 2H), 7.50 (t, $J = 7.6$ Hz, 2H), 6.87 (d, $J = 7.2$ Hz, 1H), 6.52 (d, $J = 9.2$ Hz, 1H). ^{13}C NMR (101 MHz, DMSO) δ 166.06, 162.16, 157.01, 141.84, 141.38, 138.96, 133.66, 132.80, 129.16, 127.90, 122.81, 117.11, 103.05. IR (KBr) ν : 3449, 2992, 1674, 1541, 1432, 1409, 1338, 1263. HRMS (ESI) m/z calcd for $C_{15}H_{12}N_3O_2S [M + H]^+$ 298.0645, found 298.0647.


7.2 Copies of NMR spectra














3c








3d





3d
























3k














3n


















4b








4c




4c














4e










4g





4g














8. References

- [1] P. Peng, J. Wang, H. Jiang, H. Liu, *Org. Lett.* **2016**, *18*, 5376-5379.
- [2] B. Jeon, U. Yeon, J.-Y. Son, P. H. Lee, *Org. Lett.* **2016**, *18*, 4610-4613.
- [3] D. Das, R. Samanta, *Adv. Synth. Catal.* **2018**, *360*, 379-384.